KR102420508B1 - 암 및 증식성 장애들의 치료를 위한 유사분열억제성 아마이드들 - Google Patents
암 및 증식성 장애들의 치료를 위한 유사분열억제성 아마이드들 Download PDFInfo
- Publication number
- KR102420508B1 KR102420508B1 KR1020167026016A KR20167026016A KR102420508B1 KR 102420508 B1 KR102420508 B1 KR 102420508B1 KR 1020167026016 A KR1020167026016 A KR 1020167026016A KR 20167026016 A KR20167026016 A KR 20167026016A KR 102420508 B1 KR102420508 B1 KR 102420508B1
- Authority
- KR
- South Korea
- Prior art keywords
- unsubstituted
- substituted
- examples
- cancer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461942956P | 2014-02-21 | 2014-02-21 | |
| US61/942,956 | 2014-02-21 | ||
| PCT/US2015/016928 WO2015127284A2 (en) | 2014-02-21 | 2015-02-20 | Antimitotic amides for the treatment of cancer and proliferative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160116009A KR20160116009A (ko) | 2016-10-06 |
| KR102420508B1 true KR102420508B1 (ko) | 2022-07-13 |
Family
ID=52684675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167026016A Active KR102420508B1 (ko) | 2014-02-21 | 2015-02-20 | 암 및 증식성 장애들의 치료를 위한 유사분열억제성 아마이드들 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10016398B2 (enExample) |
| EP (1) | EP3107909B1 (enExample) |
| JP (1) | JP6506313B2 (enExample) |
| KR (1) | KR102420508B1 (enExample) |
| CN (2) | CN114634483B (enExample) |
| AU (1) | AU2015218775C1 (enExample) |
| BR (1) | BR112016019161B1 (enExample) |
| CA (1) | CA2940237C (enExample) |
| ES (1) | ES2893374T3 (enExample) |
| IL (1) | IL247293B (enExample) |
| MX (1) | MX390530B (enExample) |
| RU (1) | RU2713179C2 (enExample) |
| SG (2) | SG10202000590SA (enExample) |
| WO (1) | WO2015127284A2 (enExample) |
| ZA (1) | ZA201606471B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420622B1 (en) | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
| BR112016019161B1 (pt) * | 2014-02-21 | 2022-12-20 | Frost Biologic, Inc | Amidas antimitóticas, composições farmacêuticas que as compreendem e uso das mesmas |
| CN106727583A (zh) * | 2016-12-12 | 2017-05-31 | 范旭升 | 一种治疗舒张性心衰的药物组合物 |
| US11377436B2 (en) * | 2017-07-12 | 2022-07-05 | The Brigham And Women's Hospital, Inc. | EAAT2 enhancing molecules |
| US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| WO2025248483A1 (ko) * | 2024-05-30 | 2025-12-04 | 삼진제약주식회사 | Nr2f6 억제제 및 이의 용도 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110263612A1 (en) | 2010-04-27 | 2011-10-27 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2012151355A1 (en) | 2011-05-03 | 2012-11-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| WO2013063385A1 (en) | 2011-10-28 | 2013-05-02 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| NZ522990A (en) * | 2000-06-05 | 2003-08-29 | Dong A Pharm | Novel oxazolidinone derivatives and a process for the preparation thereof |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| GB0209715D0 (en) * | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| JP2008505145A (ja) * | 2004-06-30 | 2008-02-21 | ノバルティス アクチエンゲゼルシャフト | 排出ポンプ阻害剤を用いてペプチドデホルミラーゼ阻害剤の感受性を増加するための方法 |
| EP1921066A4 (en) * | 2005-08-11 | 2010-07-07 | Takeda Pharmaceutical | Pyridylphenol compound and its use |
| AU2007211276B2 (en) * | 2006-01-31 | 2013-06-06 | Synta Pharmaceuticals Corp. | Pyridylphenyl compounds for inflammation and immune-related uses |
| ATE524465T1 (de) | 2006-11-17 | 2011-09-15 | Glaxosmithkline Llc | 2-carboxy-thiophen-derivate als viruzide |
| US20100130496A1 (en) * | 2007-04-12 | 2010-05-27 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase |
| WO2010039236A1 (en) * | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| WO2010100475A1 (en) * | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
| NZ598758A (en) * | 2009-09-11 | 2013-12-20 | Amgen Inc | N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
| WO2011142151A1 (ja) * | 2010-05-14 | 2011-11-17 | シャープ株式会社 | 携帯型情報端末およびその制御方法 |
| TWI541243B (zh) * | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| JP2014503000A (ja) * | 2011-01-21 | 2014-02-06 | アッヴィ・インコーポレイテッド | キナーゼのピコリンアミド阻害剤 |
| US8748432B2 (en) * | 2011-02-10 | 2014-06-10 | Syngenta Participations Ag | Microbiocidal pyrazole derivatives |
| BR112016019161B1 (pt) * | 2014-02-21 | 2022-12-20 | Frost Biologic, Inc | Amidas antimitóticas, composições farmacêuticas que as compreendem e uso das mesmas |
-
2015
- 2015-02-20 BR BR112016019161-7A patent/BR112016019161B1/pt active IP Right Grant
- 2015-02-20 AU AU2015218775A patent/AU2015218775C1/en active Active
- 2015-02-20 JP JP2016570919A patent/JP6506313B2/ja active Active
- 2015-02-20 WO PCT/US2015/016928 patent/WO2015127284A2/en not_active Ceased
- 2015-02-20 MX MX2016010877A patent/MX390530B/es unknown
- 2015-02-20 KR KR1020167026016A patent/KR102420508B1/ko active Active
- 2015-02-20 EP EP15710328.4A patent/EP3107909B1/en active Active
- 2015-02-20 SG SG10202000590SA patent/SG10202000590SA/en unknown
- 2015-02-20 RU RU2016135555A patent/RU2713179C2/ru active
- 2015-02-20 US US15/120,470 patent/US10016398B2/en active Active
- 2015-02-20 CA CA2940237A patent/CA2940237C/en active Active
- 2015-02-20 CN CN202210190090.XA patent/CN114634483B/zh active Active
- 2015-02-20 ES ES15710328T patent/ES2893374T3/es active Active
- 2015-02-20 CN CN201580009889.2A patent/CN106068263A/zh active Pending
- 2015-02-20 SG SG11201606869TA patent/SG11201606869TA/en unknown
-
2016
- 2016-08-16 IL IL247293A patent/IL247293B/en active IP Right Grant
- 2016-09-20 ZA ZA2016/06471A patent/ZA201606471B/en unknown
-
2018
- 2018-06-29 US US16/024,407 patent/US10772872B2/en active Active
-
2020
- 2020-09-03 US US17/011,589 patent/US11129813B2/en active Active
-
2021
- 2021-09-13 US US17/473,364 patent/US12383533B2/en active Active
-
2025
- 2025-08-12 US US19/297,804 patent/US20260034101A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110263612A1 (en) | 2010-04-27 | 2011-10-27 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2012151355A1 (en) | 2011-05-03 | 2012-11-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| WO2013063385A1 (en) | 2011-10-28 | 2013-05-02 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12383533B2 (en) | Antimitotic amides for the treatment of cancer and proliferative disorders | |
| JP5753927B2 (ja) | 有機化合物 | |
| TWI536991B (zh) | 黏著斑激酶之抑制劑 | |
| EP3083622B1 (en) | Maleimide derivatives as modulators of wnt pathway | |
| PT1258484E (pt) | Novos compostos de isoxazol e de tiazol e sua utilização enquanto fármacos | |
| US20090203667A1 (en) | Pentadienamide derivatives | |
| JP6876873B2 (ja) | 新規なフェニルピリジン誘導体およびこれを含む薬学組成物 | |
| KR20160124083A (ko) | Wnt 경로 조절제 | |
| EA036542B1 (ru) | Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора | |
| CN110831937A (zh) | 嘧啶衍生物化合物、其光学异构体或其药学上可接受的盐及包含其为有效成分的Tyro3相关疾病的预防或治疗用组合物 | |
| WO2015187094A1 (en) | Phthalimide derivatives as modulators of wnt pathway | |
| JP6569678B2 (ja) | ２−アミノチアゾール誘導体またはその塩 | |
| HK1232858B (en) | Antimitotic amides for the treatment of cancer and proliferative disorders | |
| KR20120056684A (ko) | 항암활성을 지닌 카르보아졸계 화합물 | |
| MX2014001052A (es) | Compuesto novedoso que tiene actividad inhibidora de angiogénesis, metodo para preparar del mismo, y composicion farmaceutica que comprende el mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 5 |